Tirzepatide Side Effects: What to Know About Mounjaro & Zepbound Safety

Like semaglutide, tirzepatide's most common side effects are gastrointestinal. In the SURMOUNT-1 clinical trial, the following rates were observed in the 15 mg group: nausea (31%), diarrhea (23%), constipation (11%), vomiting (12%), and decreased appetite (10%). Notably, nausea rates were somewhat lower than those seen with semaglutide in comparable trials.

Gastrointestinal side effects follow a predictable pattern — they are most pronounced during the first few weeks of treatment and after each dose escalation. The four-week intervals between dose increases in tirzepatide's titration schedule are designed to give the body time to adapt. Most patients find that GI symptoms peak within the first three to five days after an increase and then gradually improve.

Other commonly reported side effects include injection site reactions (redness, itching, or mild pain at the injection site) in about 3-5% of patients, headache, and fatigue. These are generally mild and self-limiting. Injection site reactions can often be minimized by rotating injection sites and allowing refrigerated medication to reach room temperature before injecting.

The most effective strategy for managing tirzepatide's GI side effects is dietary modification. During dose escalation periods, prioritize small, frequent meals over large portions. Aim for five to six smaller meals or snacks throughout the day rather than three large meals. This approach prevents the stomach from becoming overly full, which can trigger nausea and discomfort.

Reduce your intake of high-fat, fried, and heavily seasoned foods during the adjustment period. These foods take longer to digest and can exacerbate the delayed gastric emptying caused by tirzepatide. Instead, focus on lean proteins, whole grains, fruits, and vegetables. Bland foods like toast, crackers, rice, and broth can be helpful when nausea is at its worst.

Hydration is critical. Drink at least 64 ounces of water daily, sipping slowly throughout the day rather than drinking large amounts at once. If constipation becomes an issue, increase fiber intake gradually and consider a stool softener or osmotic laxative like polyethylene glycol. Physical activity, even a daily 20-minute walk, can significantly improve both nausea and constipation.

Because tirzepatide activates both GIP and GLP-1 receptors, there are some side effect considerations that differ from GLP-1-only medications. Some patients report more pronounced appetite suppression at higher doses, which can lead to inadequate caloric intake if not managed carefully. Consuming too few calories can result in excessive muscle loss, nutrient deficiencies, and fatigue.

Patients on tirzepatide should aim for a minimum of 1,200 calories per day for women and 1,500 calories per day for men, even if appetite is significantly reduced. Protein intake is especially important — target at least 60 grams per day, ideally 0.7 to 1.0 grams per pound of ideal body weight. If eating feels difficult, protein shakes and smoothies can help meet nutritional goals.

Hypoglycemia (low blood sugar) is uncommon with tirzepatide when used alone, but patients taking tirzepatide alongside insulin or sulfonylureas should be aware of the increased risk. Symptoms include shakiness, sweating, confusion, and rapid heartbeat. Your clinician may need to reduce doses of other diabetes medications when starting tirzepatide.

Tirzepatide carries the same boxed warning as other GLP-1 medications regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). While the relevance to humans is uncertain, patients should report any neck lumps, difficulty swallowing, or persistent hoarseness to their clinician.

Pancreatitis has been reported in rare cases during clinical trials (less than 0.5%). Symptoms include severe, persistent upper abdominal pain that may radiate to the back. Treatment should be discontinued immediately if pancreatitis is suspected. Patients with a history of pancreatitis may be at higher risk and should discuss this with their provider.

Gallbladder-related events, including gallstones and cholecystitis, occur at slightly higher rates with tirzepatide compared to placebo, consistent with what is seen during any period of rapid weight loss. Allergic reactions, though rare, have been reported and may include swelling, rash, or difficulty breathing. Diabetic retinopathy complications have been noted in patients with pre-existing eye disease.

In the SURMOUNT-1 trial, approximately 4.3% to 7.1% of participants discontinued tirzepatide due to adverse events, primarily gastrointestinal symptoms. This rate is comparable to or lower than discontinuation rates seen with semaglutide in similar trials, suggesting tirzepatide is reasonably well-tolerated by most patients.

If you decide to stop tirzepatide, discuss this with your clinician rather than stopping abruptly. While there are no dangerous withdrawal effects, appetite and weight may begin to return within weeks of discontinuation. Your clinician can help develop a plan for tapering or transitioning to another treatment if needed.

Seek immediate medical attention if you experience severe abdominal pain that does not resolve, signs of an allergic reaction (facial swelling, difficulty breathing, severe rash), symptoms of severe dehydration (dark urine, dizziness, rapid heartbeat, confusion), or any symptoms of a thyroid tumor. Report mood changes, including depression or suicidal thoughts, to your healthcare provider promptly.